Narcan

Pain, Itching, Septic Shock + 7 more

Treatment

8 FDA approvals

20 Active Studies for Narcan

What is Narcan

Naloxone

The Generic name of this drug

Treatment Summary

Naloxone is a medication used to reverse the effects of opioids, like morphine and heroin. It's used to treat opioid overdoses, which can cause dangerous symptoms like slow breathing, reduced heart rate, confusion, and unconsciousness. Naloxone is given by injection or nasal spray, or it can be found in a combination product called Suboxone that also contains buprenorphine. When taken by mouth, the naloxone in Suboxone has no effect and does not reduce the effectiveness of the opioid. The purpose of including naloxone in Suboxone is to discourage injection of the drug,

Narcan

is the brand name

image of different drug pills on a surface

Narcan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Narcan

Naloxone

1971

241

Approved as Treatment by the FDA

Naloxone, otherwise called Narcan, is approved by the FDA for 8 uses including Pain and Opioid Dependence .

Pain

Used to treat moderate Pain in combination with Pentazocine

Opioid Dependence

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Pain

Used to treat Severe Pain in combination with Pentazocine

Opioid-Related Disorders

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Opioids

Respiratory Insufficiency

Effectiveness

How Narcan Affects Patients

Naloxone is used to counteract the effects of opioid overdoses. It is short-acting, so multiple doses may be needed. It will not have any effect if a person has not taken opioids. After taking naloxone, an opioid user may experience withdrawal symptoms. It is important to remember that naloxone may not fully relieve the symptoms of an overdose if other drugs are also involved.

How Narcan works in the body

Naloxone is a drug that blocks the effects of opioids. It competes with opioids for binding to the brain's opioid receptor. If the patient has taken opioids, naloxone will reverse their effects. If the patient has not taken opioids, naloxone won't have any effect.

When to interrupt dosage

The suggested dosage of Narcan is contingent upon the diagnosed condition, including Opioid Dependence, Pain and Septic Shock. The volume of dosage is contingent upon the administration modality (e.g. Spray, metered or Tablet) featured in the table beneath.

Condition

Dosage

Administration

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Itching

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioid-Related Disorders

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Septic Shock

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Respiratory Insufficiency

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Emergency Care

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Warnings

Narcan Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Naloxone may interact with Pulse Frequency

There are 20 known major drug interactions with Narcan.

Common Narcan Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Naloxone.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Naloxone.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Naloxone.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Naloxone.

Narcan Toxicity & Overdose Risk

For those who have not taken opioids, naloxone has little to no effect. The lowest toxic dose of naloxone in mice and rats is more than 1 gram per kilogram when taken orally, 80 milligrams per kilogram when given intraperitoneally, and 286 milligrams per kilogram when given subcutaneously.

image of a doctor in a lab doing drug, clinical research

Narcan Novel Uses: Which Conditions Have a Clinical Trial Featuring Narcan?

64 active clinical trials are assessing the potential of Narcan in treating Opioids, Opioid-related pain, and other forms of pain.

Condition

Clinical Trials

Trial Phases

Emergency Care

0 Actively Recruiting

Opioids

0 Actively Recruiting

Opioid-Related Disorders

0 Actively Recruiting

Septic Shock

0 Actively Recruiting

Respiratory Insufficiency

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Pain

0 Actively Recruiting

Opioids

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1

Opioids

6 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Pain

0 Actively Recruiting

Narcan Reviews: What are patients saying about Narcan?

5

Patient Review

2/28/2011

Narcan for Decrease in Rate & Depth of Breathing due to Opioid Drug

Please be very careful with this medication. My husband found me unconscious and called for help. I was given narcan and brought to the ER where they assumed it was an accidental overdose. I was on a ventilator for four days and in CCU for another four because of the severe withdrawal symptoms caused by giving this drug to someone who has been taking narcotics for years.

5

Patient Review

1/16/2013

Narcan for Toxic Amount of Narcotics in the Body

I'm an ex-heroin addict, and a few years ago I overdosed on the drug. I stopped breathing and was unconscious for a while. Thankfully, the paramedics revived me with a shot of Narcan. It only lasted about 30 minutes, but it was enough to save my life.

5

Patient Review

7/3/2013

Narcan for Decrease in Rate & Depth of Breathing due to Opioid Drug

This treatment saved my life when I overdosed. The EMTs gave me the injection and it brought me back from the brink. I'm forever grateful for this medication.

1.3

Patient Review

12/1/2012

Narcan for Toxic Amount of Narcotics in the Body

I was admitted to the ER because they thought I might be having a heart attack. It turned out that I wasn't, but later on the next day they mistakenly thought I had drug toxicity for some reason. THIS DRUG ALMOST KILLED ME. IT SHOULD BE OUTLAWED. NEVER AGAIN WILL I LET ANYONE GIVE ME THIS.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about narcan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Narcan make you feel?

"Symptoms of the flu can include:

-Body aches -Fever -Sweating -Runny nose -Sneezing -Goose bumps -Yawning -Weakness -Shivering or trembling -Nervousness -Restlessness or irritability -Diarrhea -Nausea or vomiting -Stomach cramps -Fast heartbeat -Increased blood pressure"

Answered by AI

Can you buy over the counter Narcan?

"In most states, you need a prescription to get naloxone, or you can get it from a pharmacist following a specific protocol. You can't just buy it over the counter like other medications."

Answered by AI

What happens if you give Narcan to someone who doesn't need it?

"The drug Narcan will not have any effect on somebody who is not under the influence of opioids. Therefore, it is safe to administer the drug to someone you believe may have overdosed on opioids, even if you are not entirely sure."

Answered by AI

What is Narcan used for?

"It is a nasal spray version of naloxone, which is a medication that can rapidly reverse the effects of an opioid overdose.

NARCAN® Nasal Spray is a prescription medication used to treat an emergency opioid overdose with signs of breathing problems, severe sleepiness, or an inability to respond. It is a nasal spray version of naloxone, which is a medication that rapidly reverses the effects of an opioid overdose."

Answered by AI

Clinical Trials for Narcan

Image of Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia in Vancouver, Canada.

Educational Interventions for Opioid Use in Dentistry

Any Age
All Sexes
Vancouver, Canada

The aim of this study is to estimate the impact of providing personalized prescribing data and educational materials on opioid prescribing to dentists in British Columbia, Canada. The main research questions are: 1. What is the impact of an intervention on the use of opioids for dental pain? The intervention includes a personalized prescribing report (a "Portrait"), brief educational summary, and patient education materials; and 2. Does the impact of the intervention increase when dentists are also invited to attend facilitated audit-and-feedback group sessions and to develop a practice improvement plan? Using administrative health data, the prescribing of those in different combinations of materials in the Early Group will be compared to those in the Delayed Group to estimate the impact of the materials on prescribing by the dentists.

Waitlist Available
Has No Placebo

Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia

Colin Dormuth, ScD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Narcan clinical trials?

We made a collection of clinical trials featuring Narcan, we think they might fit your search criteria.
Go to Trials
Image of Toronto General Hospital in Toronto, Canada.

Transcutaneous Electrical Stimulation for Slow Breathing

18+
All Sexes
Toronto, Canada

After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual way they check for breathing concerns. If these monitors show that a patient's breathing has slowed down too much, nurses may wake the patient up or stimulate them using their voice or gentle physical touch to encourage deeper breaths. What is this study about? This research is testing a new approach that uses an additional monitor called capnography. Capnography helps detect slowing or stopping of breathing by measuring the carbon dioxide (CO2) exhaled by patients. If the monitor shows slowed or stopped breathing (called apnea, lasting at least 10 seconds), this study will test using a technology called transcutaneous electrical stimulation (TES) to encourage normal breathing. How does TES work? TES provides a slight, annoying sensation on the patient's skin-enough to wake them up without causing pain. This has been used in other studies to safely restore breathing after surgery. In this study, the researchers are testing whether a new automated device can deliver TES when the capnography monitor detects breathing issues. The goal is to test the feasibility (can this system work in the PACU?) and acceptability (how do patients feel about this approach?) of this technology. Who can join this study? Adults aged 18 or older who received general anesthesia and medications (opioids) for pain control during or after surgery are eligible. Patients recovering from surgery in the PACU at Toronto General Hospital may be invited to participate. Why is this study important? The study aims to reduce the risk of opioid-related breathing problems after surgery, making recovery safer and more comfortable for patients.

Recruiting
Has No Placebo

Toronto General Hospital

Have you considered Narcan clinical trials?

We made a collection of clinical trials featuring Narcan, we think they might fit your search criteria.
Go to Trials
Image of Pennsylvania Psychiatric Institute in Harrisburg, United States.

Semaglutide for Opioid Addiction

18 - 75
All Sexes
Harrisburg, PA

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Phase 2
Recruiting

Pennsylvania Psychiatric Institute (+2 Sites)

Jennifer Nyland, PhD

Have you considered Narcan clinical trials?

We made a collection of clinical trials featuring Narcan, we think they might fit your search criteria.
Go to Trials